Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates
Medtronic (MDT) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.46 per share a year ago.
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic Q4 GAAP diluted EPS of $0.82 increased 67%; non-GAAP diluted EPS of $1.62 increased 11% Q4 operating margin increased 380 basis points; Q4 non-GAAP operating margin increased 90 basis points Q4 operating profit of $1.4 billion increased 36%; Q4 non-GAAP operating profit of $2.5 billion increased 8% Cardiac Ablation Solutions Q4 revenue increased nearly 30% on strength of pulsed field ablation (PFA) products; business delivered $1.0 billion in FY25 revenue Submitted Hugoâ„¢ RAS system to the U.S. Food and Drug Administration (FDA) for a urologic indication in the first quarter of calendar 2025 Commenced largest brain-computer interface launch following U.S. FDA approval of BrainSenseâ„¢ Adaptive Deep Brain Stimulation (aDBS) Additional Key Highlights FY25 revenue of $33.5 billion, adjusted revenue of $33.6 billion, increased 3.6% as reported and 4.9% organic FY25 GAAP diluted EPS of $3.61 increased 31%; non-GAAP diluted EPS of $5.49 increased 6% FY25 operating margin increased 190 basis points; FY25 non-GAAP operating margin increased 10 basis points, 100 basis points constant currency FY25 operating profit of $6.0 billion increased 16%; FY25 non-GAAP operating profit of $8.7 billion increased 5%, 9% constant currency FY25 cash from operations of $7.0 billion; FY25 free cash flow of $5.2 billion Company returned $6.3 billion to shareholders in FY25 Dividend for Q1 FY26 increased to $0.71 per share, implying annual $2.84 per share; 48th consecutive year of dividend increases Announced today intent to separate Diabetes business into new standalone public company Q4 Financial Results Medtronic reported Q4 worldwide revenue of $8.927 billion, an increase of 3.9% as reported and 5.4% on an organic basis.
Medtronic announces intent to separate Diabetes business
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new standalone company ("New Diabetes Company"). This strategic decision for both Medtronic and New Diabetes Company will create a more focused Medtronic, with a more simplified portfolio in high margin growth markets.
Medtronic to Separate Diabetes Business
The medical device maker has been working to turn around the division over the last few years.
Will Medtronic's Earnings Move The Stock?
Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announcements in 53% of instances.
What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Continue to Hold Medtronic Stock in Your Portfolio Now?
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.
Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors
Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the closing of the recent trading day, Medtronic (MDT) stood at $83.62, denoting a +0.55% change from the preceding trading day.
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch
Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth.
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025
GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025. A news release will be issued at approximately 5:45 a.m.
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women
Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S., many women are still unaware of the risk and the importance of heart health.
